Category: Diabetes

Introduction and Objective: The increasing prevalence of type 2 diabetes (T2D) requires a novel, disease-modifying treatment to target the root cause of diabetic progression: the loss of pancreatic β cell function. Recent clinical data has shown that patients diagnosed with T2D have a >80% loss in functional pancreatic β cell mass, which is not reversed […]

Introduction and Objective: Women with T1D have increased risk of CVD. Whether CVD risk factors worsen during the menopausal transition is unclear.Methods: We conducted a secondary analysis of women who had undergone natural menopause (n=243) in the Epidemiology of Diabetes Interventions and Complications Study (EDIC), a prospective observational study of persons with T1D originally enrolled […]

Introduction and Objective: Type 1 diabetes (T1D) is characterized by T and B cell responses to pancreatic β islet cell proteins, insulitis, and β islet cell loss. Treatment of NOD mice, at 6 or 10 weeks of age, with poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CNPs) containing recombinant insulin, GAD65, and chromogranin A proteins (CNP-T1D) inhibited antigen […]

Introduction and Objective: The accumulation of adipose tissue occurs through adipocyte hypertrophy or adipogenesis, the latter refers to the proliferation and differentiation of adipose progenitor cells (APCs). Starting from middle age, adults often experience a notable increase in visceral adipose tissue mass, known as visceral adiposity, which is closely linked to a series of metabolic […]

Introduction and Objective: The Inflation Reduction Act capped out-of-pocket costs for insulin at $35 per 30-day supply for Medicare Part D beneficiaries in 2023 in a landmark policy change. This project measures the out-of-cap policy’s association with changes in out-of-pocket costs and insulin use for Part D beneficiaries. We also test whether the policy was […]

Introduction and Objective: People with T2D are at high risk for cardiovascular disease (CVD) and risk increases with poor glycemic control. This study evaluated the association between CGM use and the risk of major adverse cardiovascular events (MACE) among adults with T2D using real-world evidence.Methods: This retrospective study analyzed Truveta EHR data for people with […]

Introduction and Objective: We investigated the prevalence of organ impairment in people with T2D in primary care.Methods: People living with T2D and no prior heart disease were recruited from 5 sites and underwent standardised MRI (CoverScan) to measure fat (visceral, subcutaneous, epicardial, pericardial, hepatic, pancreatic), inflammation (hepatic, pancreatic, renal), muscle volume (myocardial, skeletal) and cardiac […]

Introduction and Objective: HDM1002 is an oral small molecule GLP-1RA under development for the treatment of T2DM and obesity. This study evaluated the efficacy and safety of HDM1002 in Chinese adult with T2DM inadequately controlled on diet and exercise(D&E) or metformin(Met).Methods: In this randomized, double-blind phase 2 study, patients were randomized in a 1:1:1:1:1 ratio […]

Introduction and Objective: Humans with obesity-related insulin resistance (IR) and metabolic dysfunction-associated steatotic liver disease (MASLD) show different mitochondrial alterations. While oxidative phosphorylation (OXPHOS) can be increased in liver, it may be decreased in visceral (VAT), but neither in subcutaneous adipose tissue (SAT) nor skeletal muscle (SM). However, it remains unclear how weight loss affects […]

Introduction and Objective: Instant blood-mediated inflammatory reaction (IBMIR) causes rapid loss of up to 50% of transplanted islet mass, primarily through inflammatory and coagulation pathways. Blocking these mediators is critical for improving graft survival. We hypothesized that aptamers targeting interleukin 1 beta (IL-1β), tumor necrosis factor-alpha (TNFα), and factor VIIa (FVIIa) could attenuate IBMIR and […]